Vincent Rajkumar: Myeloma XI / XI+
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group, shared on X:
“Myeloma XI / XI+
The head to head comparison of thalidomide and lenalidomide (CTD vs CRD) in contemporaneously randomized patients is quite interesting.
Always wondered how properly dosed thalidomide would do versus lenalidomide.
There are many reasons why lenalidomide is preferable to thalidomide specifically the differences in non heme toxicities.
We still use thalidomide as part of VDT PACE; or with VTd for treatment of patients with cast nephropathy.”
Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He also chairs the Board of directors of The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee.
His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023